AI Summary
We reviewed 266 live results for biosimilar pharmaceutical and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceuticals and Biosimilars.
Comparison Table
Recommended
Steqeyma (ustekinumab biosimilar)
Source: Celltrion Healthcare
Description
Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL).
Best for
subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users
View Details
Rating
BAT2506 (Golimumab Biosimilar)
Source: Accord BioPharma
Description
A proposed golimumab biosimilar under FDA review for use in the United States. The application includes a request for interchangeability status with the reference drug Simponi for treating inflammatory diseases.
Best for
U.S. immunology patients, interchangeable biologic seekers and specialty pharmacy distribution
View Details
Rating
Bevacizumab Biosimilar
Source: Biocon Biologics Philippines Inc.
Description
An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients.
Best for
solid tumor treatment, cancer therapy and oncology clinics
Tags
View Details
Rating
| Compare | Steqeyma (ustekinumab biosimilar) | BAT2506 (Golimumab Biosimilar) | Bevacizumab Biosimilar |
|---|---|---|---|
| Source | Celltrion Healthcare | Accord BioPharma | Biocon Biologics Philippines Inc. |
| Description | Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL). | A proposed golimumab biosimilar under FDA review for use in the United States. The application includes a request for interchangeability status with the reference drug Simponi for treating inflammatory diseases. | An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients. |
| Best for | subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users | U.S. immunology patients, interchangeable biologic seekers and specialty pharmacy distribution | solid tumor treatment, cancer therapy and oncology clinics |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Steqeyma (ustekinumab biosimilar) from Celltrion Healthcare."
I picked this because Steqeyma is a recently HSA-approved biosimilar in Singapore that will soon offer enhanced affordability through government drug subsidies.
Share this search
Related Finds